BioSpace News Archive

EDAP TMS SA, the global leader in robotic energy-based therapies, announced that the company has hired medical technology industry veteran Ryan Rhodes as Chief Executive Officer of EDAP Technomed, the Company’s U.S. subsidiary.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the Raymond James 2021 Human Health Innovation Conference

ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory viral infections, announced that it secured up to AU$32m investment and appointed Ruth Tal-Singer, Ph.D., to its Board of Directors.

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today provided a corporate update on its pipeline with recent and upcoming milestones.

Kriya Therapeutics, Inc., a fully integrated platform company pioneering a new model to develop novel technologies and therapeutics in gene therapy, announced today that Ilise Lombardo, M.D., has joined the company as Chief Medical Officer

Global Blood Therapeutics, Inc. has awarded approximately $450,000 to U.S. community-based organizations and institutions as part of the company’s 2021 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program.

Oryzon Genomics, S.A. announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) for vafidemstat is now open to conduct a Phase IIb clinical trial in patients with Borderline Personality Disorder (BPD).

Caris Life Sciences® and Elevation Oncology announced a strategic collaboration to jointly identify oncogenic fusions and mutations that are driver alterations.

Sage Therapeutics, Inc. and Biogen Inc. announced that the WATERFALL Study in patients with MDD met its primary endpoint with zuranolone 50 mg showing statistically significant improvement in depressive symptoms compared with placebo at Day 15 as assessed by the 17-item Hamilton Rating Scale for Depression total score.

To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide monoclonal antibodies compared to oral CGRP receptor antagonists in the prevention of migraine, Eli Lilly and Company will be conducting a head-to-head study comparing once-monthly injectable Emgality® with Nurtec® ODT, an orally disintegrating tablet patients take every other day.